Last reviewed 2026-04-20 · How we verify

Levodopa Ethyl Ester (ETILEVODOPA)

Phase 2 active Small molecule

Levodopa Ethyl Ester (generic name: ETILEVODOPA) is a etilevodopa drug. It is currently in Phase 2 development.

Etilevodopa works by crossing the blood-brain barrier and increasing dopamine levels in the brain.

Etilevodopa, also known as Levodopa Ethyl Ester, is a small molecule drug in the etilevodopa class. Its exact target is unknown, but it is believed to work by crossing the blood-brain barrier and increasing dopamine levels in the brain. Etilevodopa is not FDA-approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are also unknown. As a result, there is limited information available on its safety profile and efficacy. Further research is needed to fully understand the potential benefits and risks of etilevodopa.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETILEVODOPA
Drug class	etilevodopa
Modality	Small molecule
Therapeutic area	Hematology
Phase	Phase 2

Mechanism of action

Think of dopamine like a key that unlocks feelings of pleasure and motivation. When dopamine levels are low, people may experience symptoms like fatigue, depression, and difficulty moving. Etilevodopa helps increase dopamine levels, which can help alleviate these symptoms.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Levodopa Ethyl Ester CI brief — competitive landscape report
Levodopa Ethyl Ester updates RSS · CI watch RSS

Frequently asked questions about Levodopa Ethyl Ester

What is Levodopa Ethyl Ester?

Levodopa Ethyl Ester (ETILEVODOPA) is a etilevodopa drug.

How does Levodopa Ethyl Ester work?

Etilevodopa works by crossing the blood-brain barrier and increasing dopamine levels in the brain.

What is the generic name of Levodopa Ethyl Ester?

ETILEVODOPA is the generic (nonproprietary) name of Levodopa Ethyl Ester.

What drug class is Levodopa Ethyl Ester in?

Levodopa Ethyl Ester belongs to the etilevodopa class. See all etilevodopa drugs at /class/etilevodopa.

What development phase is Levodopa Ethyl Ester in?

Levodopa Ethyl Ester is in Phase 2.

Drug class: All etilevodopa drugs
Therapeutic area: All drugs in Hematology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing